Get the Stockscreener App
868.16
0.25%
3.2555
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $868.16, with a volume of 200.72K.
It is up +0.25% in the last 24 hours and down -3.86% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$864.90
Open:
$869.55
24h Volume:
200.72K
Relative Volume:
0.06
Market Cap:
$776.83B
Revenue:
$45.04B
Net Income/Loss:
$10.59B
P/E Ratio:
74.14
EPS:
11.71
Net Cash Flow:
$414.30M
1W Performance:
+5.41%
1M Performance:
-3.86%
6M Performance:
-6.22%
1Y Performance:
+12.14%
1-Day Range:
$865.74
$874.92
1-Week Range:
$819.50
$874.92
52-Week Range:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
867.99 | 776.83B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
207.59 | 369.26B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
163.35 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
75.54 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
91.98 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Shares Rise Over 2% After Key Signal - Benzinga
UBS maintains Eli Lilly stock Buy rating, $1,100 price target By Investing.com - Investing.com Australia
5 Stocks That Could Be The Next Nvidia - Benzinga
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer - NBC Philadelphia
Eli Lilly’s Mounjaro targets India’s $150 billion weight-loss market amid rising diabetes crisis - CNBCTV18
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped - The Globe and Mail
Was Jim Cramer Right About Eli Lilly and Company (LLY)? - Insider Monkey
Eli Lilly’s SWOT analysis: stock outlook strong despite challenges By Investing.com - Investing.com UK
Eli Lilly stock target holds at $1,020, Jefferies affirms Buy rating - Investing.com
UBS maintains Eli Lilly stock Neutral with $1100 target - Investing.com
UBS maintains Eli Lilly stock Neutral with $1100 target By Investing.com - Investing.com UK
UBS maintains Eli Lilly stock Buy rating, $1,100 price target - Investing.com India
Eli Lilly Unusual Options Activity - Benzinga
Is Eli Lilly and Company (LLY) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars? - Proactive Investors UK
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound - The Manila Times
Lilly, Novo expand DTC reach of obesity meds after compound win - Yahoo Finance
China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment' - MSN
Is Eli Lilly and Company (LLY) The Best Robinhood Stock to Buy According to Analysts? - Insider Monkey
Eli Lilly Introduces Mounjaro in India: Much Needed Breakthrough in Obesity and Diabetes Management - Elets
Eli Lilly and Co (LLY)'s Winning Formula: Financial Metrics and Competitive Strengths - GuruFocus.com
Eli Lilly Reverses Its Recent Run On Market Malaise. Is It A Sell? - Investor's Business Daily
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market - Reuters
Mounjaro: As Eli Lilly's blockbuster anti-obesity drug comes to India, expert lists key side effects - The Times of India
Can A Weekly Injection Fix Obesity? As Eli Lilly’s Mounjaro Enters India, Experts Weigh The Pros And Cons of Weight Loss Meds - ETV Bharat
As Eli Lilly’s popular weight loss drug enters India, doctors warn of potential misuse - The Financial Express
₹14,000 per month weight-loss shot is here to cash in on India’s obesity crisis - The Economic Times
Eli Lilly’s weight loss drug launches in India: Here are 4 things to know about Mounjaro - The Indian Express
Hello, I'm "MK Signal," an AI reporter who analyzes U.S. stock hot issues.A Buy signal for Eli Lilly.. - 매일경제
Eli Lilly launches its blockbuster weight loss drug Mounjaro in India - MSN
Eli Lilly Shares Are Up Today: What's Going On? - Benzinga
Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India - Investing.com Australia
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market - Reuters
Factbox-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market - Yahoo Finance
Weight-loss drug Mounjaro now available in India: All you need to know - Business Standard
Eli Lilly beats Novo Nordisk to launch weight-loss drug Mounjaro in India, at $50 for 5 mg vial - Bilyonaryo Business News
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here - Business Standard
Eli Lilly launches weight loss drug in India beating Novo Nordisk - Seeking Alpha
Eli Lilly Introduces Mounjaro Single-Dose Vial for Diabetes and Obesity - SMEStreet
Eli Lilly first to launch weight loss drug in obesity-hit India - BNN Bloomberg
Eli Lilly launches weight-loss drug Mounjaro in India at $50 for 5 mg vial, beating Novo Nordisk - PharmaLive
India's First Weight-Loss Drug Arrives: Eli Lilly Launches Mounjaro; Know How Much It Will Cost You - Free Press Journal
India gets first weight-loss drug as Eli Lilly launches Mounjaro - Gulf News
Eli Lilly launches weight-loss drug Mounjaro in India at Rs. 3,500 after drug regulator approval - The Economic Times
Eli Lilly beats Novo Nordisk to launch weight-loss drug Mounjaro in India - 코리아타임스
Ozempic-like weight loss drug Mounjaro launched in Indiaall you know to know - The Times of India
Eli Lilly launches drug Mounjaro in India for obesity, type 2 diabetes treatment - The Sen Times
5 Reasons It's Not Too Late to Buy Eli Lilly Stock - The Motley Fool
Eli Lilly First to Launch Weight Loss Drug in Obesity-Hit India - Bloomberg
Lilly Says Mounjaro 2.5 Mg Vial Priced At 3,500 Rupees In India -March 20, 2025 at 04:35 am EDT - Marketscreener.com
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):